
Jan 9 (Reuters) - The U.S. Environmental Protection Agency will reassess the safety of herbicide paraquat, its administrator Lee Zeldin said on Friday on X, adding that the body is requiring manufacturers to thoroughly prove that current uses are safe in real-world conditions.
Syngenta, which markets paraquat under the brand name Gramoxone, is among the herbicide's major sellers.
The Swiss-based agricultural chemical company is facing several lawsuits in the U.S., where plaintiffs allege exposure to paraquat caused them to develop Parkinson's, a degenerative brain disease that leads to loss of muscle coordination.
It has previously said there was "no credible evidence" that paraquat causes Parkinson's.
In agricultural settings, paraquat is mostly applied to soybean, corn and cotton crop fields to control invasive weeds and grasses, according to the Environmental Protection Agency.
(Reporting by Costas Pitas and Pooja Menon; Editing by Alan Barona)
LATEST POSTS
- 1
Investigating the Medical advantages of Aloe Vera - 2
Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life - 3
Moderna to complete US mRNA manufacturing network with $140 million investment - 4
Chemical leak in Oklahoma forces evacuations and leaves many ill - 5
What's Your Number one Superhuman Film Made?
Figure out How to Augment Your Rooftop Substitution Speculation
Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
Reconnecting with an old friend is a story of distance, loss and rediscovery
Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
Iran’s Crown Prince Reza Pahlavi backs protests: Join your fellow citizens in the streets
Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
The Craft of Computerized Detox: Individual Trials













